SEC-sourced researchBeta
ANAB
ANAPTYSBIO, INC
Company comparison ↗
Data passport
- CIK
- 0001370053
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 5/6
- Filing date
- Oct 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 17,157,000.0000 | Mar 3, 2026 |
| December 2024 | 91,280,000.0000 | Mar 3, 2026 |
| December 2025 | 234,603,000.0000 | Mar 3, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 234,603,000.0000 | -13,232,000.0000 | 19,697,000.0000 | 364,395,000.0000 | — | Mar 3, 2026 |
| December 2024 | 91,280,000.0000 | -145,231,000.0000 | -135,337,000.0000 | 483,834,000.0000 | — | Mar 3, 2026 |
| December 2023 | 17,157,000.0000 | -163,619,000.0000 | -120,800,000.0000 | — | — | Mar 3, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $234.6M | December 2025 | Mar 3, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $91.28M | December 2024 | Mar 3, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$13.23M | December 2025 | Mar 3, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $19.7M | December 2025 | Mar 3, 2026 | 10-K |
| Total assetsAssets | $364.4M | December 2025 | Mar 3, 2026 | 10-K |
| Total liabilities | — | — | — | — |